Key Insights

Highlights

Success Rate

73% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

14.3%

3 terminated out of 21 trials

Success Rate

72.7%

-13.8% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed with results

Key Signals

3 with results73% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (1)
P 1 (9)
P 2 (8)

Trial Status

Completed8
Recruiting5
Terminated3
Unknown2
Active Not Recruiting1
Enrolling By Invitation1

Trial Success Rate

72.7%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT03417856Enrolling By Invitation

Defining the Skin and Blood Biomarkers of Ichthyosis

NCT07538583Phase 2RecruitingPrimary

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT02113904Phase 2CompletedPrimary

Clinical Trial Using Humira in Netherton Syndrome

NCT06539507Phase 1RecruitingPrimary

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT05521438Phase 2Active Not RecruitingPrimary

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05856526Phase 2TerminatedPrimary

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

NCT06137157Phase 1RecruitingPrimary

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

NCT07280091Not Yet RecruitingPrimary

Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome

NCT05211830Phase 1CompletedPrimary

A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

NCT02081313Not ApplicableCompletedPrimary

Natural History and Biological Study of Netherton Syndrome

NCT05902663TerminatedPrimary

Natural History of Netherton Syndrome

NCT06953466Phase 2RecruitingPrimary

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056Phase 2RecruitingPrimary

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05979831Phase 1TerminatedPrimary

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

NCT04244006Phase 2UnknownPrimary

A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome

NCT05583669Phase 1CompletedPrimary

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

NCT05388903Phase 1CompletedPrimary

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

NCT03041038Phase 2Completed

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT01428297Phase 1Completed

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT00208026Phase 1CompletedPrimary

Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

Scroll to load more

Research Network

Activity Timeline